Erectile Dysfunction Clinical Trial
Official title:
A Randomized, Placebo Controlled, Double Blind, Multicenter Therapeutic Exploratory Clinical Study for the Evaluation of the Efficacy and Safety of Avanafil in the Patients With Erectile Dysfunction
This is an exploratory clinical study to presume the optimum usage and dosage for a therapeutic confirmatory study by evaluating the efficacy and safety of Avanafil 50mg, 100mg, 200mg or placebo administered orally in patients with erectile dysfunction. In conclusions, Patients with erectile dysfunction (ED) were administered placebo, Avanafil 50mg, 100mg or 200mg 30 minutes before sexual intercourse for 8 weeks.
1. Study design: Prospective, randomized, double blind, placebo-controlled, therapeutic
exploratory clinical study Usage & period One capsule was administered 30minutes before
sexual intercourse.It was administered only once a day.
[Evaluation endpoints]
1. Safety: ① Laboratory tests: Hematological Test, Blood chemical Test, Urinalysis Vital
signs: blood pressure, pulse rate ③ Adverse events and Adverse drug reaction ④12-lead
ECG
2. Efficacy
- Primary endpoint ▪ The change of erectile function (EF) domain score in the
international index of erectile function (IIEF)
- Secondary endpoint ▪ The change of success rate in sexual encounter profile (SEP)
questionnaire 2, questionnaire 3, questionnaire 4 and questionnaire 5 ▪ The change
of score in IIEF questionnaire 3 and questionnaire 4, The change of score in other
domains of IIEF, GEAQ (Global efficacy assessment question), Normal erectile
function (IIEF EF domain score ≥ 26) rate Statistical methods
1. Definition of Evaluation population Maximum efficacy evaluation population
included the subjects who satisfied inclusion criteria, who took the
investigational product at least once, who visited the hospital after taking
the investigational product, and who got the result of efficacy evaluation.
Safety-Evaluation Population consisted of the subjects who made a visit after
taking the investigational product once or more and who got follow-up safety
results
2. Initial Comparability Discrete variables were comparatively analyzed by
χ2-test, Fisher's exact test, and Successive variables were comparatively
analyzed by ANOVA test or Kruskal-Wallis test.
3. Efficacy Evaluation The change of EF domain score in the IIEF: Analysis of
covariance(ANCOVA), in which baseline was corrected, was performed to check
whether there was a difference between the placebo group and the Avanafil
groups in change of EF domain score.
The change of score in other domains of IIEF: Analysis of covariance(ANCOVA),
in which baseline was corrected, was performed to check whether there was a
difference between the placebo group and the Avanafil groups.
The change of score in IIEF questionnaire 3 and questionnaire 4: Analysis of
covariance(ANCOVA), in which baseline was corrected, was performed to check
whether there was a difference between the placebo group and the Avanafil
groups in IIEF questionnaire 3, questionnaire 4 respectively.
The change of success rate in SEP questionnaire 2, questionnaire 3,
questionnaire 4 and questionnaire 5: Analysis of covariance(ANCOVA), in which
baseline was corrected, was performed to check whether there was a difference
between the placebo group and the Avanafil groups.
GEAQ (Global Efficacy Assessment Question) : The difference of GEAQ between
groups was analyzed by χ2-test.
Normal erectile function(IIEF EF domain score ≥ 26) rate: The difference of
Normal erectile function rate between groups was analyzed by χ2-test.
The efficacy results were analyzed by Dunnett's or Bonferroni's multiple
comparison test to check whether there was a significant difference between
the placebo group and the Avanafil groups.
4. Safety Evaluation Adverse Events and Adverse Drug Reaction: The difference
between the placebo group and the Avanafil groups was compared by using
χ2-test or Fisher's exact test. Adverse events reported in study subjects
were presented by WHOART (World Health Organization Adverse Reaction
Terminology) system organ class. The adverse drug reactions, related with the
investigational product, were comparatively verified on the same method.
All statistical analyses were performed under significance level 5%, test power 80% and
two-side test.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 |